Sodium Oligomannate Capsules for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Jun 2021: Trial started, NCT05058040
  2. 27 Sep 2021: Trial registered, NCT05058040

The trials

NCT05058040: A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)

State
Under way
Phase
Phase 4
People
2,500 taking part
Started
2 Jun 2021
Primary completion
Jan 2025
Arms
GV-971
Results
None posted
  1. 2 Jun 2021: Trial started
  2. 27 Sep 2021: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.